Shanghai Pharma reports profit jump for first half 2025

Shanghai Pharmaceuticals Holding Co., Ltd. reported unaudited interim results for the six months ended June 30, 2025, showing a substantial 51.56% year-on-year increase in net profit attributable to equity holders, reaching RMB4,458,864,876.61. Total profit also surged by 41.45% to RMB6,820,820,702.73. Operating revenue grew by 1.56% year-on-year to RMB141,592,782,502.79, with pharmaceutical service revenue increasing by 2.17% to RMB129.433 billion.

The significant profit growth was primarily attributed to a one-off special gain resulting from a change in accounting treatment for Hutchison Pharmaceuticals. This occurred after the company acquired an additional 10% equity interest on April 25, 2025, increasing its total equity interest to 60%, and leading to consolidation of Hutchison Pharmaceuticals' financial results.

Despite the positive profit figures, net profit after deducting non-recurring profit or loss attributable to equity holders decreased by 22.38% year-on-year to RMB2,099,764,932.53. As of June 30, 2025, total assets increased by 7.62% to RMB238,067,056,071.37, while net cash flows from operating activities saw a substantial 91.98% rise to RMB989,256,988.89.